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Abstract
Sterile inflammatory response constitutes a main event in several neurodegener-
ative disorders. Alzheimer’s disease (AD) and Parkinson’s disease (PD), the leading 
degenerative pathologies of the central nervous system worldwide, exhibit a strong 
inflammatory component. Microglial and astrocytic reactivity, increased levels of 
inflammatory mediators, neuronal damage, and death are part of the pathological 
scenario leading to the progressive failure of the brain neuronal network. In this 
regard, the link between the toll-like receptors (TLRs)-mediated inflammatory 
cascade and the molecular hallmarks of AD and PD have been demonstrated 
elsewhere. Moreover, the long-lasting exposure to the inflammatory environment 
is considered one of the key elements leading to the establishment and progression 
of these pathologies. Accordingly, the modulation of the inflammatory response 
has emerged as a main target of new therapeutic approaches to fight these diseases. 
In this regard, and based on our previous works on this subject, we describe the 
pathological profile of both pathologies but in the inflammatory context. Thus, in 
the present chapter, we will introduce the main aspects of both diseases and how 
they interplay with the TLR-mediated response. We believe that this chapter should 
provide a concise overview of the roles of TLRs in the inflammatory cascades trig-
gered during AD and PD pathophysiology.
Keywords: neurodegeneration, neuroinflammatory response, toll-like receptors, 
Alzheimer’s disease, Parkinson’s disease
1. Introduction
The aging of the world population has been demonstrated systematically by 
several demographic studies. Regrettably, increased life expectancy has led to an 
increased prevalence of age-related disorders including neurodegenerative diseases. 
In this regard, Alzheimer’s and Parkinson’s diseases constitute the most relevant 
issues for the public health system of different countries. Accordingly, during the 
last decades, significant efforts have been committed to improve our understanding 
of the molecular cascades responsible for an altered aging process as well as for the 
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establishment and progression of neurodegenerative disorders, mainly Alzheimer’s 
disease (AD) and Parkinson’s disease (PD) [1].
Relevantly, though AD and PD possess their very own pathological character-
istics, the neuroinflammatory milieu has emerged as a central event of the chronic 
degenerative process. From the prodromal stage of these disorders up to the more 
advanced ones, inflammation seems to accompany or, in some cases, to drive the 
progression of AD and PD. Importantly, inflammation, as part of the nonspecific 
immune response, plays a critical role in maintenance of system homeostasis, allow-
ing to prevent or to control the detrimental effects induced by a wide variety of 
xenobiotics to the cellular components of the biological systems. Remarkably, from 
an unspecific harmful stimulus, a whole range of responses are triggered including 
complement cascade activation and cytokines release as well as activation of the 
immune cells located at the site of the insult. To properly eliminate the initial cause 
of distress and to repair the damaged tissue, the inflammatory response must be 
delicately balanced considering not only pro-inflammatory but anti-inflammatory 
mediators as well. Tumor necrosis factor 1 (TNF-1α), interleukins (IL-1, IL-8, 
IL-10), interferon (INF-γ), transforming growth factor 1 (TGF-1), complement 
proteins, act together to develop a coordinated response against primary, unspecific 
stimuli [2, 3]. In this regard, the compromise of this essential system relates with 
severe, and often lethal, conditions including immunodeficiency syndromes as 
well as autoimmune diseases. Relevantly, during the last decades, a lot of attention 
has been also given to the effects of chronic inflammatory condition as the start-
ing point of different degenerative conditions. Among these, neurodegenerative 
disorders, such as Alzheimer’s and Parkinson’s diseases, have found in the inflam-
matory response a critical milieu of events able to determinate the main molecular 
and cellular events verified during each of these diseases [4].
2. Central nervous system (CNS) immunocompetence
CNS is a highly specialized structure whose functions require specific microen-
vironmental conditions. Moreover, neuronal activity and, thus, the health of the 
neuronal network depend on the maintenance of ion gradients whose concentration 
differs significantly from the rest of the body compartments [5]. To ensure these 
conditions, the CNS remains partially isolated by the existence of the blood-brain 
barrier (BBB), a highly complex semipermeable cellular barrier whose main 
function is to prevent both exogenous and endogenous elements to alter the brain 
homeostasis [5–7]. Regarding the immune response, microglial population con-
stitutes the only immune system cellular representative within the brain with the 
astrocytes acting as a companion to exert immune surveillance and to act as the first 
line of response against harmful events within the brain. Although some additional 
peripheral immune cells including cluster of differentiation 11b and c (CD11b, 
CD11c)-positive cells localize to the CNS during some inflammatory conditions, 
it is believed that this situation is caused because of an altered permeability of the 
BBB as a consequence of the primary insult [8]. In this sense, the brain parenchyma 
has been defined as an anti-inflammatory environment due the increased levels of 
relevant anti-inflammatory mediators including the transforming growth factor β 
(TGFβ) and interleukin (IL)-10, preventing both the immune cell spreading across 
the CNS and an excessively strong immune response [8–10]. However, this latter 
condition does not imply that the CNS cannot answer to immune challenges; on the 
contrary, the CNS is a fully immunocompetent system, but with this mechanism 
being tightly controlled in order to avoid secondary damage caused by extensive 
inflammation and detrimental cell damage end products, such as reactive oxygen 
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species (ROS). In this context, during the last years, it has been evidenced that 
sustained inflammatory challenge, whether systemic or local to the CNS, will alter 
significantly the neuronal environment affecting severely the neuronal function 
and the health of the neuronal network. Regrettably, it has been suggested that 
prior to AD and PD establishment as well as during their progression, a chronic 
inflammatory condition has developed, contributing to the molecular alterations 
observed during these pathologies.
3. Toll-like receptors
A significant characteristic of AD and PD is that these pathologies exhibit a strong 
inflammatory component even when both are sterile conditions. In this sense, the 
innate immune system works through the pattern recognition receptors (PRRs) which 
recognize molecular patterns related to pathogens (pathogen-associated molecular 
patterns, PAMPs) and to endogenous molecules indicative of cell damage (damage-
associated molecular patterns, DAMPs), such as high-mobility group protein B1 
(HMGB1), S100 proteins, heat shock proteins (HSPs), DNA, mitochondrial DNA 
(mt-DNA), and ATP [11–15]. The toll-like receptors (TLRs) family constitutes a highly 
relevant type of PRR necessary not only to unleash the initial immune response but 
also to connect the first unspecific defense with the secondary adaptive immunity [12].
Depending on the species, 11–13 TLR subtypes can be found. Relevantly, the 
localization of these receptors within the cells differs between the different TLRs. 
In this regard, while TLRs 1, 2, 4, 5, and 6 are expressed at the cell membrane, its 
main objective being to sense the extracellular compartment, the TLRs 3, 7, 8, and 
9 are located inside the cells, mainly associated with endosomes and sensing the 
internal microenvironment for viral components, such as RNA and DNA [12, 16]. 
The presence of TLRs has been determined not only in several cell components of 
the peripheral immune system but also in the different cell types found in the brain 
including astrocytes, microglia, neurons, and oligodendrocytes, suggesting that 
each of these cell types can sense and trigger an immune response in the presence of 
different harmful molecular patterns. Interestingly, it has been demonstrated that 
not all the cells within the brain express the same pattern of TLRs. For example, 
microglia and neurons express all TLR subtypes, while astrocytes express a more 
limited repertoire, including TLR2, TLR3, TLR4, TLR9, and TLR11 [16, 17].
3.1 TLR inflammatory cascade
The signaling cascade triggered after TLRs’ activation involves the cross talk 
with several additional pathways able to critically modify cell physiology. In this 
sense, canonical TLR-mediated signaling involves the myeloid differentiation 
factor 88 (MyD88) cascade. In this pathway, TLR activation couples with MyD88 
inducing the activation of interleukin-1 receptor-associated kinase (IRAK) and, 
subsequently, the activation of the tumor necrosis factor receptor-associated factor 
6. This event allows the recruitment of the transforming growth factor-β-activated 
kinase-1 (TAK1) which, together with the TAK1-binding proteins, leads to the 
phosphorylation of IκB causing the activation of the IKK complex and the release 
of the nuclear factor-κB (NF-κB), triggering the NF-κB-dependent inflamma-
tory response [11, 18, 19]. Importantly, TLR 3 and TLR 4 can also signal via the 
TIR-containing adaptor inducing interferon-β (IFN-β) (TRIF). In this additional 
pathway, additional to the release of NF-κB, it also causes an increased expression 
of IFN-β by means of the IKKε/TANK-binding kinase-1 (TBK1)-dependent phos-
phorylation of the interferon regulatory factor 3 and 7 (IRF3 and IRF7) [7, 19, 20]. 
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The main objective of these TLR-mediated processes is to regulate the expression of 
several pro-inflammatory and anti-inflammatory mediators including IL-1, IL-6, 
IL-10, IL-11, IL-12, tumor necrosis factor (TNF), TGF, IFN, CCL2, CCL5, CXCL8, 
and CXCL10, among others [4, 11, 18, 19].
Additionally, TLR activation can also signal through complementary molecular 
pathways. Indeed, TAK1 activation also induces nemo-like kinase (NLK) and the 
c-Jun N-terminal kinases (JNK) pathway [18–21]. Similarly, MyD88 can signal 
through the phosphatidylinositide-3 kinase (PI3K)/Akt pathway, modulating the 
activity of the glycogen synthase kinase 3 β (GSK3β) [22, 23]. On the other hand, 
it has been demonstrated that TLR2 and TLR4 can activate the PI3K/Akt pathway 
through the Ras-related C3 botulinum toxin substrate 1 (Rac1), a member of 
the Rho family of GTPases [23]. Complimentarily, the Janus kinase (JAK)/signal 
transducer and activator of transcription (STAT) (JAK/STAT) pathway is known to 
respond to a variety of PAMPs/DAMPs and cytokines, including different inter-
leukins and INF-β. Relevantly, different studies have demonstrated that several 
members of the TLR family can phosphorylate different STAT members, suggesting 
a direct modulation of the JAK/STAT pathway [24, 25]. As is possible to observe, the 
molecular cascades that could be triggered secondarily to TLR activation are related 
with critical cellular processes including cell cycle modulation, apoptosis, and 
cytoskeleton remodeling, among others. This situation depicts the complexity of 
the immune response and the relevance of its modulation in the context of different 
pathologies including neurodegenerative ones, such as AD and PD.
4. Alzheimer’s and Parkinson’s diseases: Aβ/SNCA and TLRs
4.1 Alzheimer’s disease
AD constitutes the main form of dementia in the elderly population. Although, 
AD is recognized by the memory impairment and the reduced cognitive perfor-
mance, the clinical scenario starts with mood alterations at the very beginning of 
the disease followed by the compromise of the short-term memory and the loss of 
long-term memory as the pathology progresses. Histologically, AD is characterized 
by the atrophy of the frontal cortex, limbic area, and hippocampus. On the other 
hand, the molecular hallmarks of AD are the formation of the amyloid-β (Aβ) 
plaques, constituted by the aggregated forms of the amyloid-β peptide, and the 
intraneuronal formation of neurofibrillary tangles (NFTs) composed of hyperphos-
phorylated tau protein [26]. Relevantly, beyond these hallmarks, AD also exhibits 
increased oxidative stress, mitochondrial dysfunction, and chronic inflammatory 
response. Altogether, these molecular alterations will lead to synaptic damage, 
neuronal loss, and neuronal circuitry breakdown [26, 27].
Relevantly, even when genetic conditions can lead to an early onset AD presen-
tation, this accounts only for a small number of cases worldwide, with over 95% 
of the cases being termed as sporadic or late-onset AD. In this latter case, age and 
lifestyle have been defined as the main risk factors associated with the appearance 
of the disease [26, 27]. In agreement with the amyloid hypothesis of AD, these risk 
factors have a direct impact on the levels of Aβ leading to its increased production 
and subsequent accumulation within the brain [28, 29]. In this regard, different 
studies have linked the synaptic failure, mitochondrial dysfunction, tau hyper-
phosphorylation, glial activation, and neuronal death with increased levels of Aβ 
[27, 30]. Importantly, in the context of neuroinflammation, the ability of Aβ to 
induce the inflammatory response through the TLR2, TLR4, and TLR6, as well as 
their co-receptors including CD36, CD14, and CD47 has been widely demonstrated 
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[31–33]. However, it must to be noticed that systemic inflammatory conditions 
have been linked with an increased risk of AD development, suggesting that the 
pro-inflammatory mediators are able to alter brain homeostasis leading to neuronal 
damage and to the beginning of the neurodegenerative process [34–38].
4.2 Parkinson’s disease
PD corresponds to the second most common neurodegenerative disorder. PD 
is characterized by dopaminergic circuitry impairment caused by the loss of the 
dopaminergic neurons, mainly at the substantia nigra pars compacta (SNpc). 
Defined as synucleinopathy, PD exhibits neuronal inclusions of aggregated 
α-synuclein (SNCA) protein which can be located at the cell soma and/or neurites, 
forming the Lewy bodies and Lewy neurites [39]. SNCA plays relevant roles in the 
synaptic activity as it is linked with the recycling of synaptic vesicle pools [40–42]. 
Moreover, SNCA interferes with the dopamine metabolism affecting both the 
tyrosine hydroxylase, the enzyme in charge of synthetizing dopamine, and the 
dopamine transporter (DAT) [43, 44]. Similar to AD, even when the main signs 
of PD are associated with motor impairment, the pathological scenario begins 
much earlier with sleep disturbances and loss of olfaction which often passes 
unadvised to the patients or their relatives. Dementia is also an additional feature 
of the pathology and the affectation of memory can be part of the clinical picture. 
Although SNCA aggregation explains the damage to the dopaminergic neurons, 
the mechanisms behind SNCA dynamics have remained elusive [39, 45, 46]. 
Although PD can also emerge as a genetics-related disease with several genes linked 
to an early presentation, only a small proportion of the cases share this condition 
worldwide [39, 47]. In the same way, the vast majority of PD cases are linked to 
aging and lifestyle with the exposure of the patients to chemical xenobiotics, such 
as pesticides and recreational drugs being of most relevance [48]. Importantly, the 
SNCA aggregation is also related to the additional features observed during the 
pathological process, including mitochondrial dysfunction, increased oxidative 
stress, and neuroinflammation. Moreover, oxidative stress plays a central role in the 
pathophysiology of PD and the contribution of the ROS to the inflammatory milieu 
seems to be part of the establishment and progression of the disease.
Regarding the SNCA and inflammatory triggering, different researchers have 
demonstrated that depending on the aggregation status of SNCA, this protein can 
activate the TLRs, at least TLR2 and TLR4 [49–52]. Moreover, SNCA can be incor-
porated by the surrounding cells, particularly astrocytes, leading to the formation 
of SNCA inclusions also in these latter cells and helping to spread the SNCA pathol-
ogy across the brain [53, 54]. Relevantly, PD can also be influenced by the systemic 
inflammatory status. Indeed, it has been recently demonstrated that increased 
levels of inflammatory mediators favor SNCA aggregation [55, 56].
4.3 Aβ/SNCA secondary inflammatory cascade
Although we have indicated that both Aβ and SNCA can activate the TLRs, we have 
only spoken about the direct activation induced by these molecules on some represen-
tatives of the TLR family. However, we must realize that once the TLRs are activated, 
a full repertory of pro-inflammatory mediators is released to the environment. In 
this context, Aβ induces the expression of IL-1, IL-6, IL-12, TNF-α, cyclooxygenase 2 
(COX2), and the inducible nitric oxide synthase (iNOS) [57]. Additionally, because of 
the cellular damage caused, it will also induce the release of further DAMPs  
[26, 27, 58]. Similarly, TLRs activated after SNCA challenge will increase the expression 
of TNF-α, IL-6, and CXCL1 [49–51]. In the case of SNCA, the cell damage also will 
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cause the release of several DAMPs. Relevantly, the pro-inflammatory mediators and 
the subsequent DAMPs induced by Aβ and SNCA are able to further activate addi-
tional members of the TLR family, enhancing the inflammatory response. If we take 
into account that in both pathologies the levels of Aβ and SNCA are steadily increasing, 
the concept of a chronic inflammatory condition emerges as a potential mechanism to 
explain the progression of both diseases. Moreover, some of these pro-inflammatory 
mediators can also have a direct impact on the neuronal activity. Such is the case of 
the glial TNF-α-mediated expression of the AMPA receptors within the postsynaptic 
terminal. In this case, the increased production and release of TNF-α by the astrocytes, 
perhaps induced by the chronic exposure to the inflammatory stimulus, will cause the 
hyperexcitability of the neurons leading to glutamate excitotoxicity [59–62].
4.4 Microglial priming
Relevantly, an additional effect caused by Aβ and SNCA should be considered. 
It has been demonstrated that both molecules are also able to induce a phenomenon 
termed “microglial priming.” In this regard, microglial population which remains 
in a resting state when exposed to different inflammatory mediators, DAMPs, and/
or PAMPs can differentiate into two activated phenotypes, the M1 and M2. While 
the M1 is considered as a pro-inflammatory activation state, the M2 is defined as the 
anti-inflammatory microglial phenotype. Interestingly, it has been evidenced that in 
the presence of INF-γ and the TLR-mediated signaling, microglia usually undergo 
M1 transformation. Moreover, when microglia became “primed” usually changes to 
the M2 phenotype but develops a significant sensibility to new exposures to harmful 
stimuli, exhibiting an over dimensioned response and causing the abnormal rais-
ing of pro-inflammatory molecules because of a shift to the M1 phenotype [63–66]. 
Thus, Aβ and SNCA seem to be favoring not only the activation of the microglia to 
the pro-inflammatory phenotype (M1), but also the increase in the responsiveness of 
the microglia to the harmful stimuli. In both cases, the result will be an over activation 
of the microglia with the subsequent release of increased levels of pro-inflammatory 
mediators and ROS, enhancing the damage induced by the initial exposure to Aβ and 
SNCA [67–69]. Similarly, the chronic exposure to these inflammatory mediators can 
induce the repolarization of the microglia changing from the M2 to the M1 phenotype 
[70]. However, additional research is necessary to properly address the significance of 
microglial priming and the effects of the exposure to different levels of pro-inflam-
matory stimuli [71]. Indeed, the work conducted by Pourbadie and cols. [72] seems 
to suggest that low doses of TLR ligands can exert beneficial effects on the neuronal 
circuitry.
4.5 Mitochondrial dysfunction
Another feature of both pathologies is the affectation of the mitochondrial func-
tionality. Both Aβ and SNCA have the ability to interact with this critical organelle. 
While Aβ has been detected outside and inside the mitochondria being able to 
directly induce the several mitochondria-related apoptotic pathways, such as the 
B-cell lymphoma 2 (BCL2)-beclin1 (BECN1) complex [73, 74], SNCA can induce 
the activation of the mitochondrial membrane permeability transition pore, pro-
moting mitochondrial swelling and leading to mitochondrial degradation. Indeed, 
when SNCA degradation is blocked by means of proteasome inhibition, mitochon-
dria result as one of the first organelles to be affected. Moreover, TOM40, a protein 
that is part of the mitochondrial import machinery, has proven to be determinant 
of the SNCA-mediated mitochondrial failure [75–77]. Importantly, one of the most 
critical end points of the mitochondrial failure is the increased production of ROS 
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which is able to induce the activation of microglia and astrocytes as well as to trigger 
the inflammatory response mediated by the TLRs. Vice versa, the increased levels of 
pro-inflammatory mediators, such as TNF-α, induced by the activation of the TLRs 
by means of the Aβ and SNCA can also lead to mitochondrial dysfunction mainly 
through mitochondrial fragmentation [78].
5. Aging and neuroinflammation: self-conditioning to autodestruction?
Although aging constitutes a natural process, it has been considered from long 
ago as the main factor for several age-related conditions. However, we must realize 
that even when aging implies the progressive decay of several biological systems, 
the main issue with aging is the time span of exposure to different exogenous and 
potentially harmful stimuli (http://www.iarc.fr) [79, 80]. If we include the genetic 
and epigenetic heterogeneity between subjects as another factor to consider, it is 
almost evident that the aging process will follow different pathways depending on 
the particularities of each subject [81–83].
As previously mentioned, several works have evidenced the link between 
aging and neurodegenerative disorders. In the context of neuroinflammation, the 
immune system decay and a pro-inflammatory status are part of the aging process. 
Because of the increased levels of circulating inflammatory cytokines and the 
impaired performance of the cellular components involved in the immune response, 
a chronic exposure to an inflammatory environment verifies for all the biological 
systems. Regrettably, it has been demonstrated that the brain exhibits the same 
age-related pro-inflammatory deviation [84–87]. This general inflammatory status 
of the brain is currently termed as inflammaging.
In general terms, inflammaging is defined by the loss of the inflammatory 
homeostasis shifting to a pro-inflammatory condition with aging as the determi-
nant factor. Moreover, it has been evidenced that inflammaging is caused by the 
deregulated function of the inflammasomes, the intracellular structures where 
several pro-inflammatory mediators are synthetized including several cytokines 
[84, 88–90]. Moreover, some works have also suggested that inflammaging involves 
not the deregulation of TLR expression, but the signal cascades triggered after its 
activation through different microRNAs [91].
On the other hand, inflammaging can also relate with cell senescence. 
Regrettably, cell senescence also verifies in the immune system and affects the 
immune cells of both the peripheral system and the CNS. Although astrocytes are 
believed to be the only cells able to express senescence markers, different researches 
have evidenced that microglia also exhibit several age-related morphological and 
biochemical changes. Indeed, the increased levels of activation markers including 
the cluster of differentiation 11b, 11c, and 14, along with the increased production of 
TNF-α, IL-1β, IL-6, and reactive oxygen species (ROS) allow to dimension the effect 
of senescence on the physiology of the immunocompetent cells within the brain [92].
6. Concluding remarks
Inflammatory milieu is an extremely complex event. Moreover, it becomes even 
more complicated when we introduce the neurodegenerative process as part of the 
inflammatory equation. In this case, the final outcome will not only be determined 
by the production and release of the pro-inflammatory mediators and the specific 
responses triggered in the different cell types present in the brain, but it will also 
depend on the physiological status of these cells. Aging, and the differential exposure 
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to xenobiotics, will certainly determine the health status of the cells and its ability 
to answer properly to the inflammatory stimulus and to resist a pro-inflammatory 
condition. At the basis of all these processes, the molecular mechanisms triggered by 
the TLRs play a critical role during both AD and PD establishment and progression. 
Moreover, through the cross talk with additional signaling pathways, TLR cascade is 
able to interfere with different aspects of the cell physiology from energy production 
to cytoskeleton rearrangements. On the other hand, less is known regarding other 
representatives of the TLR family and their impact on AD/PD pathophysiology. For 
example, some evidence seems to suggest that while TLR9 will exert a protective 
effect in the context of the neurodegenerative process driven by Aβ and SNCA, TLR3 
will also enhance the release of pro-inflammatory mediators [93].
To date, significant evidence seems to confirm the key role of the inflammatory 
milieu in the neurodegenerative process and this situation should prompt researchers 
to increase their efforts to understand this cascade of events and to unveil the miss-
ing points of an inflammatory-based hypothesis of the neurodegenerative disorders.
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